AbCellera's $ABCL surged 38% after ABCL635 cut hot flash frequency 50% over placebo in Phase 2, outperforming Astellas' Veozah and Bayer's Lynkuet.
August 10, 2026 11:33 AM EDTUpdated 11:48 AM
AbCellera details 'striking' Phase 2 data for vasomotor symptoms treatment
AbCellera Biologics’ share price $ABCL had climbed about 31% by mid-morning Monday after the biotech shared positive data from a mid-stage hot flashes trial that …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
A single dose of ABCL635 cut hot flash frequency by 83% after four weeks, compared with 33% for placebo
AbCellera reports positive Phase 2 clinical trial results for ABCL635, a single-dose treatment for menopausal hot flashes.
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in…
AbCellera shares rise after positive ABCL635 Phase 2 results, while bullish momentum and analyst price targets point to further…
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
Angitia halts a Phase 3 disc-disease trial, Abivax prices an upsized $800M offering, and AlzeCure lands a $2.2B NeuroRestore deal…
AbCellera stock surges on ABCL635 menopause Phase 2 trial results
AbCellera Biologics Menopause Drug Data Shows 'New Efficacy Benchmark' - AbCellera Biologics (NASDAQ:ABCL
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile
What's Going on With AbCellera Biologics Stock On Wednesday? - AbCellera Biologics (NASDAQ:ABCL)
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
A Wild Day In Biotech
Attruby cruises toward blockbuster land as BridgeBio CEO spots ‘stabilizer-first’ ATTR market
